Los Angeles Capital Management LLC Buys Shares of 42,059 Solid Biosciences Inc. (NASDAQ:SLDB)

Los Angeles Capital Management LLC bought a new stake in Solid Biosciences Inc. (NASDAQ:SLDB) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 42,059 shares of the company’s stock, valued at approximately $293,000. Los Angeles Capital Management LLC owned 0.11% of Solid Biosciences as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in SLDB. Point72 DIFC Ltd purchased a new stake in shares of Solid Biosciences during the second quarter worth $58,000. Ground Swell Capital LLC purchased a new stake in shares of Solid Biosciences during the second quarter worth $76,000. Algert Global LLC purchased a new stake in shares of Solid Biosciences during the second quarter worth $82,000. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Solid Biosciences during the second quarter worth $92,000. Finally, Rhumbline Advisers purchased a new stake in shares of Solid Biosciences during the second quarter worth $191,000. Hedge funds and other institutional investors own 81.46% of the company’s stock.

Solid Biosciences Price Performance

NASDAQ SLDB opened at $4.85 on Monday. Solid Biosciences Inc. has a 1 year low of $2.21 and a 1 year high of $15.05. The company has a market capitalization of $193.78 million, a PE ratio of -1.60 and a beta of 1.92. The company has a fifty day moving average of $6.54 and a two-hundred day moving average of $7.62.

Solid Biosciences (NASDAQ:SLDB) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.12). On average, research analysts expect that Solid Biosciences Inc. will post -2.81 earnings per share for the current year.

Wall Street Analysts Forecast Growth

SLDB has been the topic of a number of recent research reports. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price objective on shares of Solid Biosciences in a research report on Thursday, November 7th. William Blair raised Solid Biosciences to a “strong-buy” rating in a report on Friday, August 30th. Barclays dropped their target price on Solid Biosciences from $18.00 to $15.00 and set an “overweight” rating on the stock in a report on Wednesday, August 14th. Chardan Capital reissued a “buy” rating and issued a $15.00 target price on shares of Solid Biosciences in a report on Monday, November 11th. Finally, JPMorgan Chase & Co. dropped their target price on Solid Biosciences from $15.00 to $12.00 and set an “overweight” rating on the stock in a report on Tuesday, November 12th. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $15.14.

About Solid Biosciences

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.